Renal carcinoma (RC): regulation of antitumoral immune responses.
Advanced renal cell carcinoma (RCC) is almost completely resistant to conventional therapeutic approaches such as chemotherapy or radiotherapy. There is growing evidence that few patients may be cured from metastatic RCC by immunotherapy. Unlike 20 years ago, current immunotherapeutic regimens are set up with pure drugs, such as recombinant cytokines. Immunotherapy interferes with a complicated network of cellular immune effectors, e.g., T-lymphocytes, macrophages and natural killer cells. The activity of immune effectors cells is regulated and fine-tuned by a variety of cytokines, e.g., interleukins and interferons which are produced predominantly by the immune effector cells themselves. It is reasonable to expect that in the near future more patients will benefit from immunotherapy for RCC as the knowledge on regulation of the immune response to tumors is rapidly increasing.
Heicappell
R
R
Department of Urology, Heinrich-Heine-Universität, Düsseldorf, Germany.
Ackermann
R
R
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000276:immunology; D007378:Interleukins / Q000276:immunology; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D016131:Lymphocyte Subsets / Q000276:immunology; D010586:Phagocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons